- Home
- FLNC vs VERA Comparison
FLNC vs VERA Comparison
Compare FLNC & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FLNC | VERA |
|---|---|---|
| Founded | 2018 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 974.7M | 1.5B |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | FLNC | VERA |
|---|---|---|
| Price | $19.75 | $51.16 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 20 | 11 |
| Target Price | $14.05 | ★ $76.60 |
| AVG Volume (30 Days) | ★ 6.5M | 1.9M |
| Earning Date | 02-09-2026 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,262,830,000.00 | N/A |
| Revenue This Year | $48.80 | N/A |
| Revenue Next Year | $19.81 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.46 | $18.53 |
| 52 Week High | $25.85 | $51.72 |
Technical Indicators
Market Signals| Indicator | FLNC | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 49.03 | 78.40 |
| Support Level | $18.46 | $47.22 |
| Resistance Level | $21.72 | $51.19 |
| Average True Range (ATR) | 2.32 | 3.55 |
| MACD | -0.45 | 0.54 |
| Stochastic Oscillator | 19.89 | 97.47 |
Price Performance
Historical ComparisonAbout FLNC Fluence Energy Inc.
Fluence Energy Inc is enabling the global clean energy transition with market-leading energy storage products and services, and digital applications for renewables and storage. Geographically, it derives a majority of its revenue from the Americas.
About VERA Vera Therapeutics Inc.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.